Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the maximum tolerated dose (MTD) and safety profile of a single-dose
administration of sibrotuzumab (50 mg) conjugated to an increasing dose of 131 I isotope.